Kymera Therapeutics (NASDAQ:KYMR) Hits New 12-Month High at $53.00

Kymera Therapeutics, Inc. (NASDAQ:KYMR) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $53.00 and last traded at $52.24, with a volume of 62422 shares trading hands. The stock had previously closed at $52.40.

Analyst Ratings Changes

A number of brokerages have commented on KYMR. Leerink Partnrs upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Leerink Partners restated an “outperform” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a report on Monday, September 9th. Oppenheimer reiterated an “outperform” rating and set a $52.00 price target on shares of Kymera Therapeutics in a research note on Wednesday, July 10th. Wells Fargo & Company increased their price objective on Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. Finally, B. Riley lifted their target price on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, July 9th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $48.67.

Kymera Therapeutics Stock Up 0.2 %

The stock has a 50-day moving average of $45.46 and a 200 day moving average of $39.16. The company has a market capitalization of $3.24 billion, a PE ratio of -20.91 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.10. The firm had revenue of $25.60 million during the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The business’s revenue was up 55.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.67) EPS. Equities analysts forecast that Kymera Therapeutics, Inc. will post -2.87 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Bruce Booth sold 453,960 shares of Kymera Therapeutics stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total value of $17,345,811.60. Following the completion of the sale, the director now owns 723,246 shares of the company’s stock, valued at approximately $27,635,229.66. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 495,605 shares of company stock valued at $19,303,364. Company insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several large investors have recently modified their holdings of the business. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Kymera Therapeutics during the 2nd quarter valued at approximately $1,910,000. Algert Global LLC lifted its position in shares of Kymera Therapeutics by 16.5% during the second quarter. Algert Global LLC now owns 32,706 shares of the company’s stock worth $976,000 after acquiring an additional 4,622 shares in the last quarter. Driehaus Capital Management LLC bought a new position in shares of Kymera Therapeutics in the second quarter worth $6,669,000. Susquehanna Fundamental Investments LLC boosted its holdings in shares of Kymera Therapeutics by 7.4% in the second quarter. Susquehanna Fundamental Investments LLC now owns 76,818 shares of the company’s stock worth $2,293,000 after acquiring an additional 5,325 shares during the period. Finally, The Manufacturers Life Insurance Company grew its position in shares of Kymera Therapeutics by 13.3% in the second quarter. The Manufacturers Life Insurance Company now owns 130,077 shares of the company’s stock valued at $3,883,000 after purchasing an additional 15,320 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.